Abstract
Background. Suitable autologous conduits may be lacking when performing coronary artery bypass grafting (CABG). The aim of this review is to determine the status of non-autologous grafts in CABG.
Methods. We conducted a literature search on MEDLINE All, Embase Classic and Embase through Ovid from 1960 to April 2020.
Results. Of the 1579 records identified, 21 studies were included in the review. The following grafts were assessed for patency: 109 homologous saphenous veins (patency rates ranged from 66.7% at a median follow-up of 8.5 months to 0% at 6–12 and 7–18 months, respectively), 29 expanded polytetrafluoroethylene (ePTFE) grafts (from 80% at a median follow-up of 5 months to 14.3% at 45 months), 12 human umbilical veins (50% at a median follow-up of 6 months), 50 Bioflow bovine internal mammary arteries (from 15.8% to 0% at a mean follow-up of 9.5 and 19 months, respectively), 39 Perma-Flow grafts (80% and 76.9% at 1–3 and 12 months, respectively), 20 No-React bovine internal mammary arteries (57.1% at a median follow-up of 28 months and 23.1% at a mean follow-up of 7 months), 40 autologous venous endothelial cell-seeded ePTFE grafts (94.7% and 81% at a mean follow-up of 27 and 60 months, respectively) and 12 autologous venous endothelial cell-seeded cryopreserved homologous veins (83.3% at a mean follow-up of 8.5 months).
Conclusions. The goal of an alternative conduit with patency and attributes that match those of autografts remains elusive. Autologous endothelial cell-seeded synthetic grafts have demonstrated promising results but require further investigation.
Methods. We conducted a literature search on MEDLINE All, Embase Classic and Embase through Ovid from 1960 to April 2020.
Results. Of the 1579 records identified, 21 studies were included in the review. The following grafts were assessed for patency: 109 homologous saphenous veins (patency rates ranged from 66.7% at a median follow-up of 8.5 months to 0% at 6–12 and 7–18 months, respectively), 29 expanded polytetrafluoroethylene (ePTFE) grafts (from 80% at a median follow-up of 5 months to 14.3% at 45 months), 12 human umbilical veins (50% at a median follow-up of 6 months), 50 Bioflow bovine internal mammary arteries (from 15.8% to 0% at a mean follow-up of 9.5 and 19 months, respectively), 39 Perma-Flow grafts (80% and 76.9% at 1–3 and 12 months, respectively), 20 No-React bovine internal mammary arteries (57.1% at a median follow-up of 28 months and 23.1% at a mean follow-up of 7 months), 40 autologous venous endothelial cell-seeded ePTFE grafts (94.7% and 81% at a mean follow-up of 27 and 60 months, respectively) and 12 autologous venous endothelial cell-seeded cryopreserved homologous veins (83.3% at a mean follow-up of 8.5 months).
Conclusions. The goal of an alternative conduit with patency and attributes that match those of autografts remains elusive. Autologous endothelial cell-seeded synthetic grafts have demonstrated promising results but require further investigation.
| Original language | English |
|---|---|
| Journal | Annals of Thoracic Surgery |
| DOIs | |
| Publication status | Published - 15 Dec 2020 |